Project Grant R01CA306913
Award Date 7/20/26
Completion Date 6/30/31
Dollars Obligated $522K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45229, USA
Similar Awards
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $533,245 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop strategies to eradicate leukemia-initiating cells through investigation of protein glutathionylation regulation. The award supports research examining how post-translational modification of proteins through glutathionylation regulates oxidative phosphorylation in acute myeloid leukemia cells and leukemia-initiating cells,...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to investigate combination approaches to acute myeloid leukemia targeting both CD123-directed NK cell engagers and BCL-2 inhibition through venetoclax. The research will employ dynamic BH3 profiling to probe mitochondrial priming mechanisms and test whether...
- The National Cancer Institute awarded St Jude Children's Research Hospital Inc. $423,188 on July 17, 2026, under the Cancer Biology Research program (CFDA 93.396) to support a five-year project on compartmentalized branched-chain amino acid metabolism in myeloid leukemia. The award funds research investigating how BCAT1, a cytosolic enzyme catalyzing branched-chain amino acid metabolism, becomes aberrantly activated in acute myeloid leukemia and drives leukemogenesis through production of...
- This $683,472 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Cincinnati to develop a novel targeted therapy for acute myeloid leukemia (AML). The key objectives are to therapeutically target the DHODH enzyme to induce AML cell differentiation, activate the immune system, and induce ferroptosis-mediated cell death. This approach aims to better differentiate AML cells from normal hematopoietic stem cells and enhance...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $388,616 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct prospective clinical validation of dynamic BH3 profiling as a functional biomarker for guiding treatment selection in patients with relapsed or refractory acute myeloid leukemia. The project develops and tests a novel assay that measures changes in apoptotic priming in leukemia cells after short ex vivo drug exposure. Dynamic...
- Grant Award Summary Cincinnati Children's Hospital Medical Center received a $530,106 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded September 11, 2025, with completion by August 31, 2030. The research project targets polyamine metabolism in leukemia stem cells (LSCs) to develop therapeutic interventions for acute myeloid leukemia (AML). The project delivers fundamental research investigating the mechanistic role of...
- The National Cancer Institute awarded The Johns Hopkins University $218,089 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test engineered natural killer cell therapy targeting acute myeloid leukemia. The funded work develops chimeric cytokine receptor (CCR)-engineered NK cells designed to attack AML-associated surface antigens and overcome AML-mediated NK cell suppression. In Aim 1, the recipient will engineer NK cells to express dual interleukin...
- The National Cancer Institute awarded Cincinnati Children's Hospital Medical Center $683,698 under Cancer Treatment Research (CFDA 93.395) on June 1, 2026, to validate VAV3 as a negative regulator of estrogen receptor alpha in B-cell acute lymphoblastic leukemia and to evaluate a novel therapeutic strategy combining VAV3 inhibition with the selective estrogen receptor degrader fulvestrant in preclinical models of relapsed and refractory B-ALL. The research addresses a critical gap in mechanistic...
- The National Cancer Institute awarded The Johns Hopkins University $155,479 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and validate an antibody-drug conjugate targeting CCRL2 for treatment of high-risk myelodysplastic syndrome and myelodysplastic syndrome-related acute myeloid leukemia, particularly in patients with TP53 mutations. The funded work includes patient-derived xenograft studies and assessment of the anti-CCRL2 ADC efficacy and safety in an...
- The National Institutes of Health National Cancer Institute awarded Oregon Health & Science University $638,915 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop HUMARROW, a primary cell model of acute myeloid leukemia and normal bone marrow designed to accelerate translational research. The award supports the creation and characterization of patient-derived cellular models that enable more efficient preclinical testing of AML therapeutics and...